Company
Mononuclear Therapeutics (MonoTx) engages in developing umbilical cord blood mononuclear cellular therapies for disease treatment and life-saving. MonoTx collects, processes and banks umbilical cord blood in compliance with the international standards for related and unrelated malignant hematologic disorders. MonoTx’s cord blood bank is AABB accredited and FDA registered. MonoTx is developing cord blood based cellular therapies for safe and effective treatment of spinal cord injury, stroke, macular degeneration, and neonatal hypoxic-ischemia encephalopathy.
